BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24349418)

  • 1. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients.
    Fatima A; Kaifeng S; Dittmann S; Xu G; Gupta MK; Linke M; Zechner U; Nguemo F; Milting H; Farr M; Hescheler J; Sarić T
    PLoS One; 2013; 8(12):e83005. PubMed ID: 24349418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro.
    Malan D; Friedrichs S; Fleischmann BK; Sasse P
    Circ Res; 2011 Sep; 109(8):841-7. PubMed ID: 21799153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.
    Comollo TW; Zou X; Zhang C; Kesters D; Hof T; Sampson KJ; Kass RS
    Channels (Austin); 2022 Dec; 16(1):173-184. PubMed ID: 35949058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
    Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
    Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the long QT syndrome with induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
    Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction.
    Malan D; Zhang M; Stallmeyer B; Müller J; Fleischmann BK; Schulze-Bahr E; Sasse P; Greber B
    Basic Res Cardiol; 2016 Mar; 111(2):14. PubMed ID: 26803770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome.
    Nieto-Marín P; Tinaquero D; Utrilla RG; Cebrián J; González-Guerra A; Crespo-García T; Cámara-Checa A; Rubio-Alarcón M; Dago M; Alfayate S; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Tamargo J; Bernal JA; Caballero R; Delpón E;
    Cardiovasc Res; 2022 Mar; 118(4):1046-1060. PubMed ID: 33576403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
    Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
    J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.
    Spencer CI; Baba S; Nakamura K; Hua EA; Sears MA; Fu CC; Zhang J; Balijepalli S; Tomoda K; Hayashi Y; Lizarraga P; Wojciak J; Scheinman MM; Aalto-Setälä K; Makielski JC; January CT; Healy KE; Kamp TJ; Yamanaka S; Conklin BR
    Stem Cell Reports; 2014 Aug; 3(2):269-81. PubMed ID: 25254341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
    Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
    Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel.
    Abriel H; Cabo C; Wehrens XH; Rivolta I; Motoike HK; Memmi M; Napolitano C; Priori SG; Kass RS
    Circ Res; 2001 Apr; 88(7):740-5. PubMed ID: 11304498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
    Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
    Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Na
    Pierre M; Djemai M; Poulin H; Chahine M
    Sci Rep; 2021 Aug; 11(1):17168. PubMed ID: 34433864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient.
    Selga E; Sendfeld F; Martinez-Moreno R; Medine CN; Tura-Ceide O; Wilmut SI; Pérez GJ; Scornik FS; Brugada R; Mills NL
    J Mol Cell Cardiol; 2018 Jan; 114():10-19. PubMed ID: 29024690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
    Bellin M; Casini S; Davis RP; D'Aniello C; Haas J; Ward-van Oostwaard D; Tertoolen LG; Jung CB; Elliott DA; Welling A; Laugwitz KL; Moretti A; Mummery CL
    EMBO J; 2013 Dec; 32(24):3161-75. PubMed ID: 24213244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmogenic calmodulin mutations disrupt intracellular cardiomyocyte Ca2+ regulation by distinct mechanisms.
    Yin G; Hassan F; Haroun AR; Murphy LL; Crotti L; Schwartz PJ; George AL; Satin J
    J Am Heart Assoc; 2014 Jun; 3(3):e000996. PubMed ID: 24958779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Rocchetti M; Sala L; Dreizehnter L; Crotti L; Sinnecker D; Mura M; Pane LS; Altomare C; Torre E; Mostacciuolo G; Severi S; Porta A; De Ferrari GM; George AL; Schwartz PJ; Gnecchi M; Moretti A; Zaza A
    Cardiovasc Res; 2017 Apr; 113(5):531-541. PubMed ID: 28158429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
    Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
    Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
    J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel.
    Wei J; Wang DW; Alings M; Fish F; Wathen M; Roden DM; George AL
    Circulation; 1999 Jun; 99(24):3165-71. PubMed ID: 10377081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.